Tg Therapeutics: 3 Key Takeaways For Long-term Investors
On its third-quarter 2026 earnings call, held on Nov. 9, 2026, TG Therapeutics (NASDAQ:TGTX) raised its full-year 2026 global revenue guidance to $1 billion. Commercial momentum for BRIUMVI, its intravenous (IV, meaning infused into a vein) antibody therapy targeting B cells for relapsing multiple sclerosis (MS, a chronic nervous system disease), is generating operating cash flow to fund pipeline expansion. Long-term investors are watching how management leverages this commercial base into new formulations and indications. Three things management said stand out.
The company raised its full-year outlook as expanding prescriber adoption drove U.S. BRIUMVI revenue up 52% year over year. Higher sales volume provides operating leverage, turning top-line growth into cash flow that funds broader clinical development.
Self-administered treatments account for roughly 35% of new anti-CD20 therapy starts. Adding a quarterly subcutaneous (subcu, injected under the skin) option allows TG Therapeutics to capture patients who prefer home administration without replacing its existing IV business.
Popular Products
-
Gas Detector Meter$311.56$155.78 -
Foldable Garbage Picker Grabber Tool$93.56$46.78 -
Portable Unisex Travel Urinal$49.56$24.78 -
Reusable Keychain Pepper Spray – 20ml$21.56$10.78 -
Camping Survival Tool Set$41.56$20.78